You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 5, 2024

CENTANY Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Centany patents expire, and when can generic versions of Centany launch?

Centany is a drug marketed by Padagis Us and is included in one NDA.

The generic ingredient in CENTANY is mupirocin. There are sixteen drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the mupirocin profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Centany

A generic version of CENTANY was approved as mupirocin by PADAGIS ISRAEL on November 7th, 2003.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for CENTANY?
  • What are the global sales for CENTANY?
  • What is Average Wholesale Price for CENTANY?
Summary for CENTANY
US Patents:0
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 87
Clinical Trials: 2
Patent Applications: 5,308
What excipients (inactive ingredients) are in CENTANY?CENTANY excipients list
DailyMed Link:CENTANY at DailyMed
Drug patent expirations by year for CENTANY
Recent Clinical Trials for CENTANY

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of MichiganPhase 2
Indiana UniversityPhase 2
University of WashingtonPhase 2

See all CENTANY clinical trials

US Patents and Regulatory Information for CENTANY

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Padagis Us CENTANY mupirocin OINTMENT;TOPICAL 050788-001 Dec 4, 2002 BX RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for CENTANY

See the table below for patents covering CENTANY around the world.

Country Patent Number Title Estimated Expiration
Germany 69900561 ⤷  Sign Up
Spain 2165723 ⤷  Sign Up
Canada 2259764 COMPOSITIONS PHARMACEUTIQUES RENFERMANT DE LA MUPIROCINE (PHARMACEUTICAL COMPOSITIONS CONTAINING MUPIROCIN) ⤷  Sign Up
European Patent Office 0933081 Compositions pharmaceutiques contenant mupirocine (Pharmaceutical compositions containing mupirocin) ⤷  Sign Up
Israel 123143 PHARMACEUTICAL COMPOSITIONS CONTAINING MUPIROCIN ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.